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Abstract
Background: The low-density lipoprotein receptor related protein 1 (LRP1) has been implicated in Alzheimer’s
disease (AD) but its signalling has not been fully evaluated. There is good evidence that the cytoplasmic domain of
LRP1 is involved in protein-protein interactions, important in the cell biology of LRP1.
Results: We carried out three yeast two-hybrid screens to identify proteins that interact with the cytoplasmic
domain of LRP1. The screens included both conventional screens as well as a novel, split-ubiquitin-based screen in
which an LRP1 construct was expressed and screened as a transmembrane protein. The split-ubiquitin screen was
validated in a screen using full-length amyloid protein precursor (APP), which successfully identified FE65 and
FE65L2, as well as novel interactors (Rab3a, Napg, and ubiquitin b). Using both a conventional screen as well as the
split-ubiquitin screen, we identified NYGGF4 as a novel LRP1 interactor. The interaction between LRP1 and NYGGF4
was validated using two-hybrid assays, coprecipitation and colocalization in mammalian cells. Mutation analysis
demonstrated a specific interaction of NYGGF4 with an NPXY motif that required an intact tyrosine residue.
Interestingly, while we confirmed that other LRP1 interactors we identified, including JIP1B and EB-1, were also
able to bind to APP, NYGGF4 was unique in that it showed specific binding with LRP1. Expression of NYGGF4
decreased significantly in patients with AD as compared to age-matched controls, and showed decreasing
expression with AD disease progression. Examination of Nyggf4 expression in mice with different alleles of the
human APOE4 gene showed significant differences in Nyggf4 expression.
Conclusions: These results implicate NYGGF4 as a novel and specific interactor of LRP1. Decreased expression of
LRP1 and NYGGF4 over disease, evident with the presence of even moderate numbers of neuritic plaques,
suggests that LRP1-NYGGF4 is a system altered early in disease. Genetic and functional studies have implicated
both LRP1 and NYGGF4 in obesity and cardiovascular disease and the physical association of these proteins may
reflect a common mechanism. This is particularly interesting in light of the dual role of ApoE in both cardiovascular
risk and AD. The results support further studies on the functional relationship between NYGGF4 and LRP1.
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The low-density lipoprotein (LDL) receptor-related pro-
tein 1 (LRP1) is a multifunctional receptor that mediates
the internalization and degradation of ligands involved
in diverse metabolic pathways [1]. LRP1, which is
expressed by many cells in the central nervous system,
including neurons and astrocytes [2,3], is synthesized as
a 600-kDa polypeptide that is subsequently cleaved by
furin in the trans-Golgi compartment into two subunits
of 515 and 85 kDa [4,5]. The 515-kDa subunit contains
the ligand binding domains and remains noncovalently
associated with the 85-kDa subunit, which includes the
transmembrane domain and a short cytoplasmic tail.
LRP1 plays an important role in several physiological
processes including embryonic development [6].
LRP1 recognizes and internalizes numerous extracellu-
lar ligands, including protease/protease inhibitor com-
plexes and apolipoprotein particles such as apolipoprotein
E (ApoE), and has an important role in intracellular sig-
naling pathways, some being mediated through tyrosine
phosphorylation sites in the cytoplasmic domain [1,7-9].
The binding of the AD-associated apolipoprotein ApoE to
LRP1 has been shown to be neuroprotective [10]. LRP1
also interacts with other AD-related proteins including
APP, BACE1 and presenilin 1 [11-13]. The cytoplasmic
tail of LRP1 contains two NPXY motifs and two dileu-
cine-based motifs and may interact with multiple adaptor
and scaffolding proteins, include PSD-95, Shc, Mint2, dis-
abled-1 (Dab1), JIP-1, JIP-2 and Fe65 [14-16]. Signaling
pathways associated with LRP1 include intracellular cyclic
adenosine monophosphate (cAMP), protein kinase
A (PKA), calcium signaling via N-methyl-D-aspartate
(NMDA) receptors [17] and mitogen-activated protein
(MAP) kinase pathway [18].
LRP1 has been shown to be associated with late onset
AD in some studies but not in others [19-21]. Age of
onset and severity of AD has also been shown to be asso-
ciated with LRP1 [19,22]. In addition, LRP1 signaling
pathways have been functionally implicated in AD since
LRP1 has been found to be associated with senile pla-
ques in AD brains along with the LRP1 ligands ApoE, a-
2 macroglobulin and APP, which themselves are geneti-
cally and functionally associated with AD [23-25]. LRP1
has been implicated as a receptor for cellular uptake of
Ab [22,26,27] as well as in the efflux of Ab at the blood
brain barrier [28]. Furthermore, LRP1 has also been
shown to promote the generation of Ab through an
interaction of the Kunitz protease inhibitor domain
(KPI) and cytoplasmic tail with APP [29,30]. The cyto-
plasmic tail alone has also been shown to promote deliv-
ery of APP to lipid raft microdomains that are enriched
with BACE1 activity [31]. These results indicate that
LRP1 plays a role in Ab generation, uptake into cells and
removal from the CNS.
LRP1 contains four putative ligand binding domains (I,
II, III and IV). The furin endopeptidase processing site is
found between the fourth ligand binding domain and the
transmembrane region. The cytoplasmic tail of LRP1
contains at least five motifs: two NPXY motifs, two dileu-
cine motifs, and one YXXL motif, each of which can have
a role in LRP1 trafficking and signaling. The YXXL motif
has been shown to serve as the dominant endocytosis sig-
nal for LRP1 [32], whereas the two NPXY motifs have
been shown to be subject to tyrosine phosphorylation
and constitute binding sites for proteins with phospho-
tyrosine binding (PTB) domains. One of the NPXY
motifs interacts with the transcription factor Fe65 [14].
In this study, we used conventional yeast two-hybrid
screens and a novel split-ubiquitin yeast two-hybrid
screen to identify novel interactors of LRP1. NYGGF4
was found to be a novel, and specific, interactor of
LRP1, whose expression is regulated by ApoE allele in a
mouse model is decreased during AD progression.
These results further implicate LRP1 as well as of the
novel LRP1 interactor, NYGGF4, in AD pathogenesis as
well as obesity and cardiovascular disease.
Results
Yeast two-hybrid analysis with cytoplasmic domains of
LRP1
Baits derived from two different cytoplasmic domain
sequences of LRP1 (Fig. 1), containing either the first or
second NPXY motif, were used to screen for interacting
proteins in a mouse brain library. One bait (LRP1-C1)
consisted of amino acids 4455-4476 of the LRP1 cyto-
plasmic domain and the other of amino acids 4497-4533
(LRP1-C2). After validating that the fusion proteins
were expressed in yeast and that each by itself did not
activate reporter gene expression, 1.1 × 10
7 colonies (for
LRP1-C1) and 2.8 × 10
7 colonies (for LRP1-C2) from an
adult mouse brain cDNA library (complexity 1 × 10
6;
Clontech) were screened. Clones identified in the screen
were re-assayed with an X-Gal filter test and those pas-
sing this test were further analyzed by retransformation
with either the LRP1 bait or with a control bait. Restric-
tion analysis and sequencing of all specific clones was
then carried out (Table 1). The results for LRP1-C2
include previously identified and validated LRP1 interac-
tors (EB-1, JIP1b) as well as novel interactors (Nyggf4,
Hnrpdl). The overlap with prior results for LRP1-C2
confirm the approach, while results for LRP1-C1 repre-
sent the first successful published screen with this
domain and identified Ric-8b, Freud-1 and the ribonu-
cleoprotein U1 as interactors.
Kajiwara et al. Molecular Neurodegeneration 2010, 5:1
http://www.molecularneurodegeneration.com/content/5/1/1
Page 2 of 11Split-ubiquitin yeast two-hybrid analyses
A novel two-hybrid method has been developed to allow
screening transmembrane proteins for interactors [33].
We first carried out this split-ubiquitin, yeast two-hybrid
screen for full-length APP695 to determine whether this
approach would identify previously validated, as well as
possibly novel, APP interactors. Because of the nature of
the screen (transmembrane bait but soluble prey), we
focused on soluble proteins and identified five specific,
unique clones (Table 2), including Fe65 and Fe65L2, as
well as rab3a, Napg, and ubiquitin b. The identification
of Fe65 proteins in this screen validated the approach
and justified its use with LRP1.
Screening the same mouse brain library with the LRP1
transmembrane mini-receptor mLRP4, we identified 1
unique soluble clone, Nyggf4 (Table 2). The specificity
of the interaction was validated, showing no interaction
in a follow up screen with irrelevant baits (p53 and
lamin A/C). It was exciting to note that Nyggf4 was
identical to the protein we previously identified with
conventional yeast two-hybrid screen using the LRP1-C2
bait (Table 1). The identification of Nyggf4 in two very
different yeast two-hybrid assays provided evidence that
this protein may be an important LRP1-interacting
protein.
Validation of the LRP1-Nyggf4 interaction
The interaction between LRP1 and Nyggf4 was con-
firmed by four additional methods. We first used a
mammalian two-hybrid system to confirm that LRP1
and Nyggf4 interact in mammalian cells (Fig. 2A).
Nyggf4 showed significant interaction with the LRP1
cytoplasmic domain in this assay. For comparison, we
included additional potential LRP1 interactors, identified
in the screen with the LRP1-C2 bait. From these latter
studies, we confirmed that both EB-1 and JIP1b were
LRP1 interactors in this system (Fig. 2A).
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Figure 1 Schematic of LRP1. The 515-kDa extracellular region of LRP1 consists of four domains: I, II, III and IV. The 85-kDa intracellular region of
LRP1 includes two NPXY motifs.
Table 1 Results of traditional yeast two-hybrid screens
Prey Number of clones Accession number
Using LRP1-C1 as bait
Ric-8b 3 NM_001013441
Freud-1 1 NM_145970
Small nuclear ribonucleoprotein U1 1 NM_009224
Using LRP1-C2 as bait
JIP1b 22 NM_011162
EB-1 3 XM_001003394
Nyggf4 3 NM_001003948.1
Hnrpdl 1 NM_016690
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domain interacting proteins identified by us and by
others (e.g., JIP1b and EB-1, [34,35]) have also been
reported to interact with APP. We therefore sought to
determine whether Nyggf4 could interact with APP (Fig.
2B). Using the mammalian two-hybrid system, we
observed that under conditions where JIP1b and EB-1
could bind the cytoplasmic domain of APP, Nyggf4
could not. The Nyggf4 interaction shows specificity to
LRP1 in these studies, while JIP1b and EB-1 do not, as
they bind both LRP1 and APP.
We also confirmed an interaction between LRP1 and
NYGGF4 using GST pulldown, coimmunoprecipitation
and colocalization studies. For the GST pulldowns, a
fusion protein comprised of GST and the LRP1-intracel-
lular domain (GST-LICD), but not GST alone, could
precipitate NYGGF4, when it was expressed in COS-7
cells (Fig. 3A).
Subsequently, FLAG-mLRP4 and NYGGF4-V5 were
cotransfected into H4 neuroglioma cells, and immuno-
precipitation of either protein by FLAG or V5 antibody
successfully coprecipitated the other protein as detected
by immunoblot (Fig. 3B). Furthermore, both proteins
showed extensive colocalization, especially in the peri-
nuclear region, when cotransfected into either H4 cells
or Neuro 2A cells (Fig. 3C).
Characterization of the LRP1-Nyggf4 interaction
We next used the mammalian two-hybrid system to
determine whether the LRP1-Nyggf4 interaction
required the intact NPVY motif of the LRP1-C2 domain
(Fig. 4). Nyggf4 interacted with wild-type LRP1
Table 2 Results of the split-ubiquitin yeast two-hybrid
screens
Prey Number of clones Accession number
Using APP695 as bait
Fe65 1 NM_009685
Fe65l2 1 NM_146085
Rab3a 1 NM_009001
Napg 1 NM_028017.1
Ubiquitin b 1 NM_011664.3
Using mLRP4 as bait
Nyggf4 2 NM_001003948.1
Figure 2 Mammalian two-hybrid assays with the LRP1 or APP cytoplasmic domains. H4 human neuroglioma cells were transfected with
the indicated constructs, and luciferase activity measured. A. The LRP1 cytoplasmic domain was cloned into the pBIND vector while the
interactors JIP-1b, EB-1 and Nyggf4 were cloned into the pACT vector. Strong interactions between LRP1 and JIP-1b, EB-1 or Nyggf4 were
observed, confirming results with yeast two hybrid studies. B. The APP cytoplasmic domain (known as APP intracellular domain/AICD) was
cloned into pBIND, while the interactors JIP-1b, EB-1 and Nyggf4 were cloned into pACT. Strong interactions between JIP-1b or EB-1 with the
APP intracellular domain were observed but no interaction was observed with Nyggf4 and the APP intracellular domain. ***, P < 0.0001.
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V5 cloned into pcDNA3.1V5/His and resultant cell lysates were subjected to GST-pulldown with either GST or with GST-LRP1 (cytoplasmic
domain only), as indicated by the scheme at the base of the figure. Aliquots of cell lysates (right most lanes) and aliquots of the GST-pulldowns
were probed by immunoblotting with anti-V5 antibody for NYGGF4. NYGGF4 is precipitated with GST-LRP1, but not with GST alone. B. FLAG-
tagged mLRP4 and V5-tagged NYGGF4 were cotransfected into H4 neuroglioma cells, and immunoprecipitation (IP) of either protein by FLAG or
V5 antibody successfully coprecipitated the other protein as detected by immunoblot (IB). Lysate was also blotted to show expression in
transfected cells (Input) and control immunoprecipitations were carried out with purified control immunoglobulin (IgG). C. FLAG-tagged mLRP4
and V5-tagged NYGGF4 were cotransfected into either H4 (upper) or Neuro 2A (lower) cells, and detected by immunocytochemistry. Both
proteins showed extensive colocalization, especially in the perinuclear region. Results are representative of three independent experiments.
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the NPVY motif in C2 domain was mutated to NAVA.
In contrast, mutating the NPTY motif in C1 domain to
NATA in the LRP1 domain had no effect on Nyggf4
binding. This indicated both that the binding of Nyggf4
involved a canonical NPXY motif and was specific for
the motif in LRP1-C2.
Expression of NYGGF4 mRNA in Alzheimer’s disease
Given the potential role for NYGGF4 as an LRP1-inter-
acting protein and a role for LRP1 in AD, we then
asked whether there was altered expression of mRNA
for Nyggf4 and LRP1 in that disease (Fig. 5A). Expres-
sion of human NYGGF4 was significantly reduced in
probable and definite AD as compared to age-matched
controls (F1,88 = 15.419, p < 0.001). Interestingly, expres-
sion of NYGGF4 decreased over the progression of the
disease, as assessed by either CDR scores (F6,90 =3 . 9 1 7 ,
p < 0.01; data not shown), Braak stage (F5,82 = 8.979,
p < 0.001; data not shown), or increasing plaque density
(F3,94 = 4.096, p < 0.01; Fig. 5B). The levels of NYGGF4
decreased with even the smallest increase in plaque den-
sities. The associations between NYGGF4 levels and dis-
ease progression all demonstrated highly significant
linear trends (F1,95 = 17.425, p < 0.01 for CDR score,
F1,85 = 25.053, p < 0.001 for Braak stage, and F1,96 =
13.102, p < 0.001 for plaque density).
LRP1 was also significantly reduced (39% reduction) in
probable and definite AD, as compared to age-matched
controls (F1,88 = 15.877, p < 0.001; Fig. 5A). LRP1
expression also showed decreased expression over the
course of disease, as measured by CDR score, Braak
stage, or plaque load (Fig. 5B, and data not shown). The
decrease in LRP1 with increasing Braak stage was signif-
icant (F5,82 = 5.462, P < 0.001) and the linear trend was
significant as well (F1,86 = 9.381, p < 0.01). Although the
decrease of LRP1 with increasing CDR score was not
significant (F6,90 = 1.65, p = 0.143), the linear trend was
significant (F1,95 = 4.832, p < 0.05). Finally, LRP1 expres-
sion was significantly reduced (30% for group 1, 37% for
group 2, and 54% for group 3, all compared to group 0)
Figure 4 Mammalian two-hybrid assays with wild-type and mutant LRP1. NPXY motifs of the cytoplasmic domain of LRP1 were mutated
and the interaction of the cytoplasmic domain with Nyggf4 was assessed as described in Fig. 2. NATA represents the mutation of the NPXY
motif of LRP1-C1 and NAVA represents the mutation of NPXY motif of LRP1-C2. Nyggf4 binds to wild-type LRP1 and to LRP1-NATA but not to
LRP1-NAVA. *, P < 0.01; ***, P < 0.001.
Figure 5 Expresssion of LRP1 and NYGGF4 in Alzheimer disease. A. Expression of LRP1 and NYGGF4 in entorhinal cortex (BA28/36),
comparing controls and subjects with AD. ***, p < 0.001 B. Expression of LRP1 and NYGGF4 as a function of neuritic plaque density. Plaque
density scores are derived from counts across five cortical regions: 0, no neuritic plaques; 1, 1-6 plaques per mm
2; 2, 7-12 plaques per mm
2; and,
3, >12 neuritic plaques per mm
2. ***, p < 0.001 for negative linear trend.
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p < 0.001; Fig. 5B) with a strong negative linear trend
(F1,96 = 22.215, p < 0.001).
Expression of Nyggf4 mRNA in mouse models for
Alzheimer’s disease
Subsequently, we asked whether there was altered expres-
sion of mRNA for Nyggf4 and Lrp1 in mice with different
human APOE isoforms, as LRP1 is a major receptor for
APOE and APOE is a major AD risk factor (Fig. 6). Inter-
estingly, expression of Nyggf4 was significantly upregu-
lated in mice carrying human APOE ε4 gene compared to
mice carrying human APOE ε2 and human APOE ε3g e n e
(F1, 17 = 5.992, p < 0.001 and F1,17, = 0.008, p < 0.01,
respectively). Furthermore, expression of Lrp1 was signifi-
cantly decreased in these mice (F1, 17 = 0.312, p < 0.001
for APOE ε2a n dF 1,17, = 16.463, p < 0.01, for APOE ε3
respectively). For comparison, Bace1 levels were
unchanged in the mice while another Lrp1-binding pro-
tein, Lrpap showed increased expression in the ApoE4
mice, similar to Nyggf4 (F1, 17 = 2.695, p < 0.05 for APOE
ε2a n dF 1,17, = 1.012, p = 0.079, for APOE ε3 respectively).
Discussion
In the current study, we screened for novel interactors
of the LRP1 intracellular domain using both conven-
tional and split-ubiquitin screens (see Fig. 1). Two sepa-
rate baits, each encompassing one of the two NPXY
motifs of the LRP1 intracellular domain (Figure 1), were
used in the conventional screens (Table 1). For the
split-ubiquitin screen, mLRP4, which consisted of
domain IV, transmembrane and cytoplasmic tail of
LRP1 (Figure 1) was used, after validating the approach
with full-length APP (Table 2). NYGGF4 was identified
as an LRP1 interactor using both LRP1-C2 in the con-
ventional screen as well as in the slit-ubiquitin screen
(Tables 1 and 2). This interaction was validated as
specific in yeast, as well as in mammalian two-hybrid
screens and in colocalization and coprecipitation experi-
ments. We observed that the interaction of NYGGF4
with LRP1 is mediated by the NPVY sequence in LRP1.
Interestingly, unlike other LRP1-binding proteins, which
can also interact with APP, NYGGF4 was shown to bind
LRP1 but not APP, indicating that the NYGGF4-LRP1
interaction shows specificity not seen with some other
interactors.
NYGGF4 is a 250 amino acid cytoplasmic protein that
is largely defined by single PTB domain. Amongst the
clones identified in this study, all contained the PTB
domain with flanking sequence supporting a role for
t h i sP T Bd o m a i ni nt h ei n t e raction with LRP1. This
conclusion is supported by a recent study that used
numerous PTB domains to screen for interacting pro-
teins [36]. In that study, the PTB domain of NYGGF4
(there identified as Q7Z2X4), was shown to pull down a
complex of LRP1 and cubulin, the latter previously asso-
ciated with megalin, which is another member of the
LDLR family.
Altogether, NYGGF4 remains a poorly characterized
gene that was first identified as a gene showing
increased expression in obese subjects [37]. Those stu-
dies demonstrated high expression of NYGGF4 in adi-
pose tissue, heart and skeletal muscle and showed that
NYGGF4 increased proliferation of 3T3-L1 preadipo-
cytes. Later studies by the same group showed a role for
NYGGF4 in glucose homeostasis in mature adipocytes,
with increased expression of NYGGF4 leading to
reduced insulin-stimulated glucose uptake and impaired
insulin-stimulated GLUT4 translocation [38]. When fed
with a high fat, high sucrose (diabetogenic) diet to
induce obesity, ApoE deficient mice showed no differ-
ences in plasma lipid levels, lipoprotein profiles or
atherosclerotic lesion areas [39] and are hence resistant
to many of the effects of the diabetogenic diet. In a
similar vein, disruption of LRP1 in adipocytes led to a
delayed postprandial lipid clearance, reduced body
weight, smaller fat stores, lipid-depleted brown adipo-
cytes, and improved glucose tolerance, while showing
resistance to dietary fat-induced obesity and glucose
intolerance [40]. These results, when taken together
with our studies, lead us to hypothesize that the
LRP1-NYGGF4 interaction may mediate critical effects
of LRP1 on diet-induced obesity, glucose tolerance, and
cardiovascular risk factors. In support of this, review of
SNPs in NYGGF4 analyzed in a large study [41] indicate
that two (rs2215598 and rs6739369) show nominal asso-
ciation with hypertension (P = 0.00021 and P = 0.00008,
respectively).
The very strong association of ApoE with AD also
raises the question as to the role of ApoE receptors
such as LRP1, and the molecules associated with them,
Figure 6 Expression of Lrp1, Nyggf4, Bace1, and Lrpap in a
mouse model of Alzheimer’s disease. Relative mRNA expression
levels of Bace1, Lrp1, Lrpap, and Nyggf4 from whole brain tissue of
mice expressing either the ApoE2, ApoE3, or ApoE4 isoform. All
values are normalized to three ubiquitously expressed housekeeping
genes (Actb, Gapdh, and Rpl13a using qBase. *, p < 0.05, **, p <
0.01, and ***, p < 0.001.
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NYGGF4 is decreased in AD (Fig. 5). Moreover the
levels of NYGGF4, as well as LRP1, decreased as a func-
tion of disease progression, particularly as defined by
increasing neuritic pathology. Further studies would
need to address the mechanisms of altered expression of
these genes in AD progression, which might include loss
of neurons as well as additional mechanisms. Interest-
ingly, the functional linkage between ApoE, LRP1, and
NYGGF4 receives support from our observations in
ApoE-transgenic mice, where ApoE genotype modulates
expression of Lrp1 mRNA and expression of Nyggf4
mRNA in opposite directions. The mechanism for this
would require further experimentation, however it
appears that levels of this ApoE binding protein and its
associated adaptor are regulated by ApoE isoforms in
such a way that would likely lead to alterations in down-
stream signaling. How this might modulate cardiovascu-
lar risk or cognitive function is of course a very
interesting question for future studies.
Conclusions
Extensive proteomic analyses, including yeast-two hybrid
screening, mammalian two-hybrid screening, coprecipta-
tion, and colocalization, identify NYGGF4 as an LRP1-
binding protein. NYGGF4 is not well studied but
appears well situated to mediate the effects of LRP1 on
aspects of obesity, glucose tolerance, and cardiovascular
risk factors. Moreover, the relationship between ApoE
genotype and NYGGF4 expression supports an impor-
tant relationship between these two proteins in AD risk.
Further study of NYGGF4 in the CNS and the periphery
will clarify the role of the protein in physiological pro-
cesses and in disease.
Methods
Two-hybrid screening
All yeast two-hybrid screening was carried out together
with Dualsystems Biotech (Zurich). For conventional yeast
two-hybrid screening, baits flanking either the first (LRP1-
C1,
4445KRRVQGAKGFQHQRMTNGAMNVEIGNP-
TYKMY
4476) or second (LRP1-C2,
4497KPTNFTNPVYA-
TLYMGGHGSRHSLASTDEKRELLGR
4533) NPXY motifs
of LRP1 (shown above in bold lettering) were cloned into
the DUALhybrid bait vector in frame with the LexA
DNA-binding domain, and the resultant construct con-
firmed by sequencing. After validating that baits, by them-
selves, did not activate reporter gene expression, an adult
mouse brain cDNA library was screened (Clontech,
Mountain View, CA). Bait dependency of each putative
clone was confirmed by retransforming into strains carry-
ing either the relevant LRP1 construct or a control vector.
All remaining baits were then sequenced.
Split-ubiquitin yeast two-hybrid screening, which has
the advantage that it allows for screening with mem-
brane-inserted transmembrane proteins, was carried out
as previously described [33]. To first validate the
method, we used full-length amyloid precursor protein
(APP) as bait, onto which we fused (at the COOH-term-
inal) the COOH-terminal portion of ubiquitin ("Cub”,
see [33]) and an artifical transcription factor (LexA-
VP16). A mouse brain cDNA library with a mutated
version of the amino-terminal portion of ubiquitin
("NubG”, see [33]), fused to the amino-terminal of prey
sequences was used to screen for potential positive
interactors. Specific clones remaining after false positives
were eliminated by the use of irrelevant baits (p53 and
lamin A/C) were sequenced.
Since LRP1 is a large protein not readily expressed in
heterologous systems, minireceptors that include ligand-
binding domains of LRP1 have been generated [42]. The
minireceptor mLRP4 consists of the signal peptide, a
FLAG tag, and the entire sequence from ligand binding
domain IV through the COOH-terminal of the native
receptor. As with APP, Cub and an artificial transcrip-
tion factor (LexA-VP16) were fused to the COOH-term-
inal of mLRP4 (a gift of Dr. Guojun Bu) and screening
was carried out as described above.
GST pulldown experiments
GST pulldowns were carried out as previously described
[43]. Briefly, COS-7 cells were transfected with control
vector or with NYGGF4-V5 using Lipofectamin 2000
(Invitrogen), according to the manufacturer’si n s t r u c -
tions, and lysed after 24-48 hrs. Subsequently, purified
GST or GST fused to the cytoplasmic domain of LRP1
(beginning at the KRR membrane anchor) previously
incubated with glutathione beads were incubated with
100 μg of cell lysate. After washing three times with
wash buffer, beads were boiled in SDS sample buffer
and run on 10% SDS-PAGE gel. Proteins were analyzed
by immunoblotting and ECL detection.
Mammalian two-hybrid assays
To confirm interactions in mammalian cells, the Check-
mate mammalian two-hybrid system (Promega) was
used according to manufacturer’s instructions. H4 neu-
roglioma cells were transfected with various combina-
tions of vectors expressing the following proteins: a
naked GAL4 DNA binding domain (pBIND); a GAL4
DNA binding domain fused to the intracellular domain
of LRP1 (pBIND-LRP1; again beginning at the KRR
membrane anchor) or APP (pBIND-APP); a naked VP16
transactivation moiety activation domain (pACT); a
VP16 transactivation moiety fused to JIP1b (pACT-
JIP1b), EB-1 (pACT-EB-1) or Nyggf4 (pACT-Nyggf4)
(the lower case font for Nyggf4 here and elsewhere in
the manuscript is to indicate that the murine sequence
was used). A reporter construct with a GAL4 consensus
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sequence was also cotransfected in all conditions. Inter-
actions were monitored by transactivation of luciferase
expression. Both firefly luciferase (reflecting gene activa-
tion) and Renilla luciferase (reflecting transfection effi-
ciency) were measured in the same sample at the same
time, leading to much reduced noise. Data were
obtained from three or more independent experiments
and expressed as a ratio of firefly luciferase to Renilla
luciferase expression (Firelfy/Renilla).
Coimmunoprecipitation experiments
H4 neuroglioma cells were cotransfected with FLAG-
mLRP4 and NYGGF4-V5 plasmids for 24 hours using
Fugene6. Cells were lysed in lysis buffer containing 1%
Triton X100 and protease inhibitor cocktail in 1× phos-
phate buffer saline (PBS). 100 μg of lysates were dis-
solved in 500 μl of lysis buffer and incubated with 5 μg
of antibody or control IgG for 2 hours, then with addi-
tional Protein-G agarose beads for 1 hour at 4°C. Beads
were washed with wash buffer containing 0.5% Triton
X100 in PBS three times and then boiled in SDS loading
buffer. Immunoblotting was performed as described in
GST pulldown.
Colocalization experiments
H4 or Neuro-2A cells were cotransfected with FLAG-
mLRP4 and NYGGF4-V5 using Fugene6 (Roche) for 24
hours and immunostained with rabbit 1704 anti-LRP1
and mouse anti-V5 antibodies, then subsequently with
AlexaFluor 488 anti-rabbit IgG and AlexaFluor 594 anti-
mouse IgG (Invitrogen) antibodies. The 1704 anti-LRP1
antibody was kindly provided by Dr. Edward Koo.
Gene expression in postmortem brains
All assessments and post-mortem procedures were
approved by the Institutional Review Boards of Pilgrim
Psychiatric Center, Mount Sinai School of Medicine,
and the James J. Peters VA Medical Center. Subject
selection, cognitive assessment and neuropathological
assessment were carried out as previously described
[44]. Briefly, frozen post-mortem brain tissue from the
entorhinal cortex (Brodmann area 28/36) of subjects
diagnosed with or without AD (normal neuropathology,
N = 33; definite AD, N = 52; probable AD, N = 9; possi-
ble AD, N = 8) were obtained from the Mount Sinai/
Bronx Veterans Administration (VA) Medical Center
Department of Psychiatry Brain Bank. Normal controls
had no history of any psychiatric or neurological disor-
ders and no discernible neuropathological lesions.
Neuritic plaque density was quantified in 5 cortical
regions [Brodmann area 9 (BA9; middle frontal gyrus),
Brodmann area 45/47 (BA45/47; orbital frontal gyrus),
Brodmann area 21/22 (BA21/22; superior temporal
gyrus), Brodmann area 39 (BA39; inferior parietal cor-
tex), and Brodmann area 17 (BA17; calcarine cortex)],
as previously described [45]. The results from these
analyses were then used to bin the samples into gour
groups: Samples with a score of 0, corresponded to
those with no plaques observed in the 5 cortical regions;
a score of 1 was used for samples with only 1-6 neuritic
plaques per mm
2; and a score of 2 and 3 were used for
samples with 7-12 and >12 neuritic plaques per mm
2,
respectively.
Total RNA extraction and reverse transcriptase (RT)
reactions were performed after DNAse treatment and
template RNA quality, including degradation and DNA
contamination, were controlled. Taqman® probes for
endogenous control gene (RPLP0, Hs99999902_m1;
GUSB, Hs99999908_m1; B2M, Hs99999907_m1) and
experimental probes (LRP1, Hs01059330_m1; NYGGF4,
Hs00952182_m1) were purchased from Applied Biosys-
tems Inc. and the reactions were carried out with Taq-
Man® Universal PCR Master Mix (430437, Roche) using
ABI Prism 7900HT at Mount Sinai Quantitative PCR
Shared Research Facility. Expression levels of each sam-
ple were normalized to the geometric mean of GUSB,
B2M, and RPLP0 expression levels.
Gene expression in mouse models for Alzheimer’s disease
Male APOE knock-in (KI) mice, homozygous for human
APOE *2, *3 and *4 were originally obtained from Taco-
nic (Germantown, NY, USA) and a colony maintained
at the Animal Resources Centre (ARC, Perth, Western
Australia). These mice have been previously described
[46-50]. RNA was extracted from whole brain of male
C57BL mice expressing either the apolipoprotein ε2
(ApoE2) (n = 10), ApoE3 (n = 10), or ApoE4 (n = 9)
isoform using an RNeasy Mini-Prep Kit (Qiagen). The
quality of all RNA samples was measured using an RNA
6000 Nano Kit (Agilent Technologies) and each sample
used for subsequent cDNA synthesis possessed an RNA
Integrity Number (RIN) of 0.9 or higher. cDNA was
generated from total RNA extracts using a High Capa-
city cDNA Archive Kit (Applied Biosystems) as per
manufacturer instruction. mRNA levels of Bace1, Lrp1,
Lrpap,a n dNyggf4 were determined via qPCR using the
appropriate TaqMan UPL probe and primer sets
(Applied Biosystems). Four ubiquitously expressed
housekeeping genes (Actb, Gapdh, 18s,a n dRpl13a)
were used as references and all data was normalized
using qBase [51]. qBase selected three of the housekeep-
ing genes (Actb, Gapdh,a n dRpl13a)a se n d o g e n o u s
references based on their geometric mean expression.
Statistical analyses
Statistical analyses were performed using SPSS 11.0 soft-
ware. For mammalian two- hybrid data, a t-test was
used to compare effects of either LRP1 or APP on Fire-
fly/Renilla ratio with each of the interactors or to vector
alone. For expression data, an ANCOVA was carried
out with LRP1 and NYGGF4 as dependent variables and
either case status, CDR score, Braak Stage, or neurtic
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NYGGF4 expression were not normally distributed,
NYGGF4 data was log transformed. In each analysis, we
used post-mortem interval, sex, sample pH, or ApoE4
allele as covariates if they were associated with the
dependent variable. Sex showed no associations in LRP1
expression versus CDR score and Braak stage and was
therefore omitted from the analysis. We also assessed
the linear relationship by linear regression analysis con-
trolling for covariates. All data are presented as means ±
SEM and significant findings were noted when p < 0.05.
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